Retroviral intasome assembly and inhibition of DNA strand transfer
Open accessThe DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
Integrase is an essential retroviral enzyme that binds both termini of linear viral DNA and inserts them into a host cell chromosome. The structure of full-length retroviral integrase, either separately or in complex with DNA, has been lacking. Furthermore, although clinically useful inhibitors of HIV integrase have been developed, their mechanism of action remains speculative. Here we present a crystal structure of full-length integrase from the prototype foamy virus in complex with its cognate DNA. The structure shows the organization of the retroviral intasome comprising an integrase tetramer tightly associated with a pair of viral DNA ends. All three canonical integrase structural domains are involved in extensive protein-DNA and protein-protein interactions. The binding of strand-transfer inhibitors displaces the reactive viral DNA end from the active site, disarming the viral nucleoprotein complex. Our findings define the structural basis of retroviral DNA integration, and will allow modelling of the HIV-1 intasome to aid in the development of antiretroviral drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“The structures revealed unexpected architectural diversity among intasomes from different retroviral genera.”
From Structure and function of retroviral integrase (2022) · cites this paper as [25]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Consistent with their function, all intasomes feature 2-fold symmetry and harbour a pair of juxtaposed active sites engaged with 3’ vDNA ends.”
From Structure and function of retroviral integrase (2022) · cites this paper as [25]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Within the CIC, the IN dimers are bridged via the exchange of associated NTDs and are joined by a pair of CTDs (referred to as the synaptic CTDs), which act as rigid spacers.”
From Structure and function of retroviral integrase (2022) · cites this paper as [25]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“While the intasomes from the prototype foamy virus (PFV, a simiispumavirus) as well as the δ-retroviruses HTLV-1 and simian T-cell lymphotropic virus (STLV) contain four IN subunits (arranged as a dimer-of-dimers)25,29,37,38”
From Structure and function of retroviral integrase (2022) · cites this paper as [25]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Despite these differences, all intasomes incorporate the conserved intasome core (CIC) assembly, which is the minimal functional unit and is represented by the PFV structure (Figs. 2A, 3).”
From Structure and function of retroviral integrase (2022) · cites this paper as [25]
Experimental — accuracy not yet measured
8 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Coot : model-building tools for molecular graphics
Emsley, P., & Cowtan, K. (2004) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444904019158 · Cited by 30,571
Phaser crystallographic software
McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C., & Read, R. J. (2007) · Journal of Applied Crystallography · doi:10.1107/s0021889807021206 · Cited by 20,612
The CCP4 suite: programs for protein crystallography
Collaborative Computational Project, N. 4. (1994) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444994003112 · Cited by 17,270
Refinement of Macromolecular Structures by the Maximum-Likelihood Method
Murshudov, G. N., Vagin, A. A., & Dodson, E. J. (1997) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444996012255 · Cited by 14,742
The interpretation of protein structures: Estimation of static accessibility
Lee, B., & Richards, F. M. (1971) · Journal of Molecular Biology · doi:10.1016/0022-2836(71)90324-x · Cited by 5,850
PRODRG: a tool for high-throughput crystallography of protein–ligand complexes
Schüttelkopf, A. W., & van Aalten, D. M. F. (2004) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444904011679 · Cited by 4,804
MolProbity: all-atom contacts and structure validation for proteins and nucleic acids
Davis, I. W., Leaver-Fay, A., Chen, V. B., Block, J. N., Kapral, G. J., Wang, X., Murray, L. W., Arendall, W. B., Snoeyink, J., Richardson, J. S., et al. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkm216 · Cited by 3,896
The Buccaneer software for automated model building. 1. Tracing protein chains
Cowtan, K. (2006) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444906022116 · Cited by 1,822
Use of TLS parameters to model anisotropic displacements in macromolecular refinement
Winn, M. D., Isupov, M. N., & Murshudov, G. N. (2001) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444900014736 · Cited by 1,696
Gouet, P. (2003) · Nucleic Acids Research · doi:10.1093/nar/gkg556 · Cited by 1,509
Research works printed but not linked: 2
- Grobler, J. A., Stillmock, K., Miller, M. D. & Hazuda, D. J. Mechanism by which the HIV integrase active-site mutation N155H confers resistance to raltegravir. Antivir. Ther. 13 (suppl. 3). A41 (2008)
- Leslie, A. G. W. Recent changes to the MOSFLM package for processing film and image plate data. Joint CCP4 and ESF-EAMCB Newsletter on Protein Crystallography no. 26, (1992)
Cited by
Items 101–200 of 719
HIV DNA is heavily uracilated, which protects it from autointegration
Yan, N., O’Day, E. M., Wheeler, L. A., Engelman, A., & Lieberman, J. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1102943108 · Cited by 72
“Indeed, the recently solved structure of the prototype foamy virus (PFV) IN multimer in complex with DNA oligomers revealed that the major groove is severely widened and minor groove compressed at the site of integration (44, 45).”
BackgroundSelf-citationEmerging trends in metalloprotein inhibition
Rouffet, M., & Cohen, S. M. (2011) · Dalton Transactions · doi:10.1039/c0dt01743d · Cited by 77
Rational design of 2-pyrrolinones as inhibitors of HIV-1 integrase
Ma, K., Wang, P., Fu, W., Wan, X., Zhou, L., Chu, Y., & Ye, D. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.09.054 · Cited by 67
The hepatitis B virus ribonuclease H as a drug target
Tavis, J. E., & Lomonosova, E. E. (2015) · Antiviral Research · doi:10.1016/j.antiviral.2015.04.002 · Cited by 72
“Like the RNaseH inhibitors, the integrase inhibitors usually function by binding to and chelating the divalent cations in the active site (Agrawal et al., 2012; Espeseth et al., 2000; Hare et al., 2010; Hazuda et al., 2009), although binding of the inhibitors is strengthened in many cases by interactions with both the…”
BackgroundHajimahdi, Z., Zarghi, A., Zabihollahi, R., & Aghasadeghi, M. R. (2012) · Medicinal Chemistry Research · doi:10.1007/s00044-012-0241-5 · Cited by 64
“Recently, Hare et al. (2010) solved the crystal structures of full-length prototype foamy virus (PFV) IN DNA complexes with various HIV-1 IN inhibitors, exhibiting two-metal ions in the strand transfer active site (Mg or Mn).”
HIV integrase as a target for antiretroviral therapy
Hazuda, D. J. (2012) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0b013e3283567309 · Cited by 63
Billamboz, M., Bailly, F., Lion, C. J., Calmels, C., Andréola, M., Witvrouw, M., Christ, F., Debyser, Z., Luca, L. D., Chimirri, A., et al. (2010) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2010.11.033 · Cited by 64
Key determinants of target DNA recognition by retroviral intasomes
Serrao, E., Ballandras-Colas, A., Cherepanov, P., Maertens, G. N., & Engelman, A. N. (2015) · Retrovirology · doi:10.1186/s12977-015-0167-3 · Cited by 62
“The location of secondary structural elements has been documented crystallographically for HIV-1 [89], ASLV [90], SIV [91], and PFV [2] INs.”
BackgroundSelf-citationAllosteric Inhibitor Development Targeting HIV‐1 Integrase
Al‐Mawsawi, L. Q., & Neamati, N. (2011) · ChemMedChem · doi:10.1002/cmdc.201000443 · Cited by 61
Murine Leukemia Viruses: Objects and Organisms
Rein, A. R. (2011) · Advances in Virology · doi:10.1155/2011/403419 · Cited by 80
“MLV IN has not been characterized in detail but is presumed to function as a tetramer [68, 69].”
BackgroundEvolution of Foamy Viruses: The Most Ancient of All Retroviruses
Rethwilm, A., & Bodem, J. (2013) · Viruses · doi:10.3390/v5102349 · Cited by 74
4-Substituted 2-Hydroxyisoquinoline-1,3(2H,4H)-diones as a Novel Class of HIV-1 Integrase Inhibitors
Billamboz, M., Suchaud, V., Bailly, F., Lion, C. J., Demeulemeester, J., Calmels, C., Andréola, M., Christ, F., Debyser, Z., & Cotelle, P. (2013) · ACS Medicinal Chemistry Letters · doi:10.1021/ml400009t · Cited by 63
Investigating the Role of Metal Chelation in HIV-1 Integrase Strand Transfer Inhibitors
Bacchi, A., Carcelli, M., Compari, C., Fisicaro, E., Pala, N., Rispoli, G., Rogolino, D., Sanchez, T. W., Sechi, M., Sinisi, V., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200851g · Cited by 64
Kawasuji, T., Johns, B. A., Yoshida, H., Taishi, T., Taoda, Y., Murai, H., Kiyama, R., Fuji, M., Yoshinaga, T., Seki, T., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm3010459 · Cited by 61
The development of novel HIV integrase inhibitors and the problem of drug resistance
Wainberg, M. A., Mésplède, T., & Quashie, P. K. (2012) · Current Opinion in Virology · doi:10.1016/j.coviro.2012.08.007 · Cited by 71
“Briefly, an allosteric hindrance between the halogenated phenyl group and the 30 dinucleotide cleaved during 30 processing prevents the efficient binding of INSTIs before 30 processing can take place [29,34].”
BackgroundStructural Biology of HIV Integrase Strand Transfer Inhibitors
Jozwik, I. K., Passos, D. O., & Lyumkis, D. (2020) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2020.06.003 · Cited by 78
Costi, R., Métifiot, M., Esposito, F., Crucitti, G. C., Pescatori, L., Messore, A., Scipione, L., Tortorella, S., Zinzula, L., Novellino, E., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm401040b · Cited by 60
Serrao, E., Krishnan, L., Shun, M.-C., Li, X., Cherepanov, P., Engelman, A., & Maertens, G. N. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku136 · Cited by 59
“Previous structure-based PFV/HIV-1 amino acid sequence alignments (2,27) were analyzed to identify potential functional analogs of PFV IN residues Ala188, Arg329 and Arg362.”
Self-citationInteraction of the HIV-1 Intasome with Transportin 3 Protein (TNPO3 or TRN-SR2)
Larue, R., Gupta, K., Wuensch, C., Shkriabai, N., Kessl, J. J., Danhart, E., Feng, L., Taltynov, O., Christ, F., Van Duyne, G. D., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.384669 · Cited by 59
“We show for the first time that TNPO3 can affectively bind the functional IN-viral DNA stable synaptic complex in 34054 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 287 • NUMBER 41 • OCTOBER 5, 2012 vitro.”
BackgroundMethodInfluentialResistance to HIV integrase inhibitors
Mésplède, T., Quashie, P. K., & Wainberg, M. A. (2012) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0b013e328356db89 · Cited by 63
“These drugs contain a halogenated phenyl group that invades the catalytic pocket and displaces the 30 viral end [30,34] and three coplanar oxygen atoms that chelate the divalent ions within the catalytic pocket, thus inhibiting the activity of the catalytic DDE triad [4,6,26,35–37].”
BackgroundRibeiro, A. J. M., Ramos, M. J., & Fernandes, P. A. (2012) · Journal of the American Chemical Society · doi:10.1021/ja304601k · Cited by 62
Deanda, F., Hightower, K. E., Nolte, R. T., Hattori, K., Yoshinaga, T., Kawasuji, T., & Underwood, M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0077448 · Cited by 64
“[22], while the IN-DNA-DTG model was assembled based on”
BackgroundMethodInfluentialCosti, R., Métifiot, M., Chung, S., Cuzzucoli Crucitti, G., Maddali, K., Pescatori, L., Messore, A., Madia, V. N., Pupo, G., Scipione, L., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm5001503 · Cited by 55
Zeng, L., Wang, Y., Kazemi, R., Xu, S., Xu, Z.-L., Sanchez, T. W., Yang, L.-M., Debnath, B., Odde, S., Xie, H., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm300667v · Cited by 59
Metal ions and the extracellular matrix in tumor migration
Stelling, M. P., Motta, J. M., Mashid, M., Johnson, W. E., Pavão, M. S. G., & Farrell, N. P. (2019) · FEBS Journal · doi:10.1111/febs.14986 · Cited by 57
3-Hydroxypyrimidine-2,4-diones as an Inhibitor Scaffold of HIV Integrase
Tang, J. Y., Maddali, K., Métifiot, M., Sham, Y. Y., Vince, R., Pommier, Y. G., & Wang, Z. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm1014378 · Cited by 60
Bar-Magen, T., Donahue, D. A., McDonough, E. I., Kuhl, B. D., Faltenbacher, V. H., Xu, H., Michaud, V., Sloan, R. D., & Wainberg, M. A. (2010) · AIDS · doi:10.1097/qad.0b013e32833cf265 · Cited by 60
“Resistance mutations such as N155H are thought to interfere with coordination of bound Mg2þ, thereby affecting drug binding in the catalytic core [15].”
BackgroundQuinoline-based HIV Integrase Inhibitors
Musioł, R. (2013) · Current Pharmaceutical Design · doi:10.2174/1381612811319100008 · Cited by 61
Engelman, A. N., & Cherepanov, P. (2017) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2017.04.005 · Cited by 56
“com NED, NTD, and CTD of the outer IN subunits, which are disordered in all PFV intasome crystal structures [2,4 ,5,6], are dispensable for catalytic function in vitro [35].”
BackgroundSelf-citationStructure-Guided Optimization of HIV Integrase Strand Transfer Inhibitors
Zhao, X. Z., Smith, S. J., Maskell, D. P., Métifiot, M., Pye, V. E., Fesen, K., Marchand, C., Pommier, Y., Cherepanov, P., Hughes, S. H., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00596 · Cited by 54
Self-citationViral Integration and Consequences on Host Gene Expression
Desfarges, S., & Ciuffi, A. (2012) · Springer eBooks · doi:10.1007/978-94-007-4899-6_7 · Cited by 80
“…to its oligomeric state: IN dimers bound to LTR termini catalyze the 3 ¢ processing whereas concerted integration requires IN tetramers (Cherepanov et al. 2011 ; Delelis et al. 2007 ; Diamond and Bushman 2005 ; Faure et al. 2005 ; Guiot et al. 2006 ; Hare et al. 2010 ; Jaskolski et al. 2009 ) .”
BackgroundProbing chelation motifs in HIV integrase inhibitors
Agrawal, A., DeSoto, J., Fullagar, J. L., Maddali, K., Rostami, S., Richman, D. D., Pommier, Y. G., & Cohen, S. M. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1112389109 · Cited by 57
“This was further corroborated by a recent crystal structure of the prototype foamy virus (PFV) integrase bound to its cognate DNA (intasome) (14).”
InfluentialTekeste, S. S., Wilkinson, T. A., Weiner, E. M., Xu, X., Miller, J. T., Le Grice, S. F. J., Clubb, R. T., & Chow, S. A. (2015) · Journal of Virology · doi:10.1128/jvi.01471-15 · Cited by 51
“Structural studies of the prototype foamy virus (PFV) intasome found the tetramer to be the active IN configuration (9, 11, 12).”
BackgroundIntegrase Inhibitors Effective against Human T-Cell Leukemia Virus Type 1
Seegulam, M. E., & Ratner, L. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01413-10 · Cited by 54
New first and second generation inhibitors of human immunodeficiency virus-1 integrase
Pendri, A., Meanwell, N. A., Peese, K. M., & Walker, M. A. (2011) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2011.586631 · Cited by 60
“This binding configuration was recently confirmed by an X-ray crystallographic study of raltegravir and elvitegravir bound to prototype foamy virus integrase [15,16].”
BackgroundDeciphering the Code for Retroviral Integration Target Site Selection
Santoni, F. A., Hartley, O., & Luban, J. (2010) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1001008 · Cited by 54
“A tetramer of the viral integrase protein (IN) [14] cleaves the ends of the viral cDNA to produce recessed 39OH and free CA dinucleotides at the terminus of each long terminal repeat (LTR) [15].”
BackgroundAmplification, Next-generation Sequencing, and Genomic DNA Mapping of Retroviral Integration Sites
Serrao, E., Cherepanov, P., & Engelman, A. N. (2016) · Journal of Visualized Experiments · doi:10.3791/53840 · Cited by 53
“Here, we present a detailed protocol for (1) generation of diverse libraries of retroviral integration sites using ligation-mediated PCR (LM-PCR) amplification and next-generation sequencing (NGS), (2) mapping the genomic location of each virus-host junction using BEDTools, and (3) analyzing the data for statistical r…”
MethodSelf-citationCrosby, D. C., Lei, X., Gibbs, C. G., McDougall, B. R., Robinson, W. E., & Reinecke, M. G. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm1010594 · Cited by 53
The Mu story: how a maverick phage moved the field forward
Harshey, R. M. (2012) · Mobile DNA · doi:10.1186/1759-8753-3-21 · Cited by 52
“Structures of intasomes captured at various stages of the integration of the retrovirus PFV (prototype foamy virus), also show a trans arrangement of catalytic subunits, with target DNA accommodated in a severely bent conformation in the strand transfer complex [27,34].”
Peat, T. S., Rhodes, D. I., Vandegraaff, N., Le, G., Smith, J. A., Clark, L. J., Jones, E. D., Coates, J. A. V., Thienthong, N., Newman, J., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0040147 · Cited by 52
“Raltegravir has been confirmed to bind at the active site of IN by crystallography [41].”
BackgroundKessl, J. J., Li, M., Ignatov, M., Shkriabai, N., Eidahl, J. O., Feng, L., Musier-Forsyth, K., Craigie, R., & Kvaratskhelia, M. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkr581 · Cited by 52
“We then employed our FRET results to position CTDs in the supporting subunits, which are absent in the reported crystal structure (32).”
BackgroundMethodInfluentialRhodes, D. I., Peat, T. S., Vandegraaff, N., Jeevarajah, D., Le, G. T., Jones, E. D., Smith, J. A., Coates, J. A. V., Winfeld, L. J., Thienthong, N., et al. (2011) · Antiviral chemistry & chemotherapy · doi:10.3851/imp1716 · Cited by 52
“Furthermore, mutagenesis studies have demonstrated that the mobility of this loop is important for catalytic activity [3] and different conformations of the loop and active site have been observed in model systems with and without integrase inhibitors [4].”
BackgroundMethodInfluentialWang, Z., Tang, J. Y., Salomon, C. E., Dreis, C. D., & Vince, R. (2010) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2010.05.004 · Cited by 51
Raltegravir: the first HIV‐1 integrase strand transfer inhibitor in the HIV armamentarium
Nguyen, B., Isaacs, R., Teppler, H., Leavitt, R. Y., Sklar, P. A., Iwamoto, M., Wenning, L. A., Miller, M. D., Chen, J., Kemp, R. K., et al. (2011) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2011.05972.x · Cited by 55
Pescatori, L., Métifiot, M., Chung, S., Masoaka, T., Crucitti, G. C., Messore, A., Pupo, G., Madia, V. N., Saccoliti, F., Scipione, L., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00159 · Cited by 53
Ty3, a Position-specific Retrotransposon in Budding Yeast
Sandmeyer, S. B., Patterson, K., & Bilanchone, V. (2015) · Microbiology Spectrum · doi:10.1128/microbiolspec.mdna3-0057-2014 · Cited by 54
“The first crystal structure of a retrovirus IN, that of prototypic foamy virus IN complexed oligonucleotides representing cDNA ends and target DNA provided insight into this class of proteins (148, 149).”
BackgroundCyclic peptide inhibitors of HIV-1 integrase derived from the LEDGF/p75 protein
Hayouka, Z., Hurevich, M., Levin, A., Benyamini, H., Iosub‐Amir, A., Maes, M., Shalev, D. E., Loyter, A., Gilon, C., & Friedler, A. (2010) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2010.09.046 · Cited by 53
Doxycycline has distinct apicoplast-specific mechanisms of antimalarial activity
Okada, M., Guo, P., Nalder, S.-A., & Sigala, P. A. (2020) · eLife · doi:10.7554/elife.60246 · Cited by 48
“be mechanistically akin to diketo acid inhibitors of HIV integrase like raltegravir that bind to active 209 site Mg2+ ions to inhibit integrase activity but are displaced by exogenous metals (19, 20).”
BackgroundFan, X. H., Zhang, F.-H., Al-Safi, R. I., Zeng, L., Shabaik, Y., Debnath, B., Sanchez, T. W., Odde, S., Neamati, N., & Long, Y. (2011) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2011.06.058 · Cited by 56
Retroviral Vectors: Post Entry Events and Genomic Alterations
Nowrouzi, A., Glimm, H., Kalle, C. V., & Schmidt, M. (2011) · Viruses · doi:10.3390/v3050429 · Cited by 51
“The basic molecular mechanism of retroviral integration has been demonstrated in biochemical studies in vitro [45] and has been further elucidated by recent structural work [46,47].”
BackgroundThe evaluation of catechins that contain a galloyl moiety as potential HIV-1 integrase inhibitors
Jiang, F., Chen, W., Yi, K., Wu, Z., Si, Y., Han, W., & Zhao, Y. (2010) · Clinical Immunology · doi:10.1016/j.clim.2010.08.007 · Cited by 50
“Hare et al [33] published the X-ray structure of full-length integrase in combination with its cognate DNA in 2010.”
BackgroundPanwar, U., & Singh, S. K. (2017) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2017.1384400 · Cited by 49
Intasome architecture and chromatin density modulate retroviral integration into nucleosome
Benleulmi, M. S., Matysiak, J., Henriquez, D. R., Vaillant, C., Lesbats, P., Calmels, C., Naughtin, M., Leon, O., Skalka, A. M., Ruff, M., et al. (2015) · Retrovirology · doi:10.1186/s12977-015-0145-9 · Cited by 47
“Although numerous partial structures of INs from different retroviral genera have been determined, only PFV IN has been crystallized in its full-length form, in the presence of its DNA substrates, providing unprecedented details on the organization of the successive nucleoprotein complexes involved in the integration…”
BackgroundInfluentialA Homology Model of HIV-1 Integrase and Analysis of Mutations Designed to Test the Model
Johnson, B. C., Métifiot, M., Ferris, A., Pommier, Y., & Hughes, S. H. (2013) · Journal of Molecular Biology · doi:10.1016/j.jmb.2013.03.027 · Cited by 47
Pommier, Y. G., Kiselev, E., & Marchand, C. (2015) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2015.07.032 · Cited by 56
Bimodal high-affinity association of Brd4 with murine leukemia virus integrase and mononucleosomes
Larue, R. C., Plumb, M. R., Crowe, B. L., Shkriabai, N., Sharma, A., DiFiore, J., Malani, N., Aiyer, S. S., Roth, M. J., Bushman, F. D., et al. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku135 · Cited by 44
“The NTD contains the NTD-extension domain (NED) (32) and the Zn-binding motif (HH-CC type) and is thought to help IN multimerization.”
BackgroundProgress in HIV-1 Integrase Inhibitors: A Review of their Chemical Structure Diversity.
Hajimahdi, Z., & Zarghi, A. (2016) · PubMed Central · Cited by 68
Structures of a RAG-like transposase during cut-and-paste transposition
Liu, C., Yang, Y., & Schatz, D. G. (2019) · Nature · doi:10.1038/s41586-019-1753-7 · Cited by 44
“In contrast, Mos1 23,24 and retroviral integrases 19,21,34 adopt very similar structures before and after target DNA capture.”
HIV-1 Integrase Multimerization as a Therapeutic Target
Feng, L., Larue, R. C., Slaughter, A., Kessl, J. J., & Kvaratskhelia, M. (2015) · Current Topics in Microbiology and Immunology · doi:10.1007/82_2015_439 · Cited by 45
“…the structural organization of the IN subunits in the SSC emerged from the breakthrough crystal structures of prototype foamy virus (PFV) intasome [(Hare et al. 2010a, b, 2012; Maertens et al. 2010), reviewed in (Cherepanov 2010; Li et al. 2011; Cherepanov et al. 2011; Engelman and Cherepanov…”
BackgroundRose, K. M., Ferreira‐Bravo, I. A., Li, M., Craigie, R., Ditzler, M. A., Holliger, P., & DeStefano, J. J. (2019) · ACS Chemical Biology · doi:10.1021/acschembio.9b00237 · Cited by 65
Going beyond Integration: The Emerging Role of HIV-1 Integrase in Virion Morphogenesis
Elliott, J. L., & Kutluay, S. B. (2020) · Viruses · doi:10.3390/v12091005 · Cited by 51
“These drugs bind to the active site of the IN CCD, displacing the reactive 3’ end of the viral DNA and preventing its insertion into the host DNA [73].”
BackgroundMohammed, K. D., Topper, M. B., & Muesing, M. A. (2011) · Journal of Virology · doi:10.1128/jvi.02374-10 · Cited by 44
“Cross-linking (32, 42) and complementation (25, 73) studies of HIV-1 IN support a model in which the CTD of one subunit (analogous to the unresolved CTD of an outer PFV intasome subunit) binds subterminal viral LTR DNA, stabilizing the viral DNA terminus in the active site of the opposing subunit (the inner PFV intaso…”
BackgroundThe emerging diversity of transpososome architectures
Dyda, F., Chandler, M., & Hickman, A. B. (2012) · Quarterly Reviews of Biophysics · doi:10.1017/s0033583512000145 · Cited by 49
“It is also possible that 3k-processing can also be accomplished without major rearrangements (unlike, e.g., Mos1) although the structure of the PFV intasome before 3k-processing has not yet been reported.”
BackgroundInfluentialGijsbers, R., Vets, S., De Rijck, J., Ocwieja, K. E., Ronen, K., Malani, N., Bushman, F. D., & Debyser, Z. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.255711 · Cited by 44
RetractedJohnson, B. C., Métifiot, M., Pommier, Y. G., & Hughes, S. H. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.05292-11 · Cited by 48
“85 Å, these values show that the active sites of the three structures are quite similar (28).”
BackgroundMethodInfluential3-Hydroxypyrimidine-2,4-dione-5-N-benzylcarboxamides Potently Inhibit HIV-1 Integrase and RNase H
Wu, B., Tang, J. Y., Wilson, D. J., Huber, A. D., Casey, M. C., Ji, J., Kankanala, J., Xie, J., Sarafianos, S. G., & Wang, Z. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00040 · Cited by 44
“1-(Hydroxy)-4-(ethylamino)-1,2,3,6-tetrahydro-2,6-dioxo-Nphenylpyrimidine-5-carboxamide (48)—White solid, 83% yield; 1H NMR (600 MHz, DMSO-d6): δ 11.”
BackgroundCorona, A., Leva, F. S. D., Rigogliuso, G., Pescatori, L., Madia, V. N., Subra, F., Delelis, O., Esposito, F., Cadeddu, M., Costi, R., et al. (2016) · Antiviral Research · doi:10.1016/j.antiviral.2016.09.008 · Cited by 45
Structural basis of host protein hijacking in human T-cell leukemia virus integration
Bhatt, V., Shi, K., Salamango, D. J., Moeller, N. H., Pandey, K. K., Bera, S., Bohl, H. O., Kurniawan, F., Orellana, K., Zhang, W., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16963-6 · Cited by 39
Métifiot, M., Maddali, K., Johnson, B. C., Hare, S., Smith, S. J., Zhao, X. Z., Marchand, C., Burke, T. R., Hughes, S. H., Cherepanov, P., et al. (2012) · ACS Chemical Biology · doi:10.1021/cb300471n · Cited by 44
Self-citationPflieger, A., Téguo, P. W., Papastamoulis, Y., Chaignepain, S., Subra, F., Munir, S., Delelis, O., Lesbats, P., Calmels, C., Andréola, M., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0081184 · Cited by 44
“The recent crystallization of the intasome of another retrovirus, the human prototype foamy virus (PFV), provided many insights into the functional organization of the protein inside these active complexes [10,11].”
BackgroundSharma, H., Sanchez, T. W., Neamati, N., Detorio, M., Schinazi, R. F., Cheng, X., & Buolamwini, J. K. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.09.009 · Cited by 42
HIV-1 IN Strand Transfer Chelating Inhibitors: A Focus on Metal Binding
Bacchi, A., Carcelli, M., Compari, C., Fisicaro, E., Pala, N., Rispoli, G., Rogolino, D., Sanchez, T. W., Sechi, M., & Neamati, N. (2011) · Molecular Pharmaceutics · doi:10.1021/mp100343x · Cited by 42
Zhao, X. Z., Smith, S. J., Maskell, D. P., Metifiot, M., Pye, V. E., Fesen, K., Marchand, C., Pommier, Y., Cherepanov, P., Hughes, S. H., et al. (2016) · ACS Chemical Biology · doi:10.1021/acschembio.5b00948 · Cited by 42
Self-citationRegulated complex assembly safeguards the fidelity ofSleeping Beautytransposition
Wang, Y., Pryputniewicz-Dobrinska, D., Nagy, E.-E., Kaufman, C. D., Singh, M., Yant, S. R., Wang, J., Dalda, A., Kay, M. A., Ivics, Z., et al. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw1164 · Cited by 46
“(a) CAACTG-----AA-----TTGAA (3) (b) CAACT ---CAAA -----TGAA (2) (c) CAACTG---GA-------TTGAA (4) (d) CAACT-----CGA------TTGAA (1) (e) CAACT—--CAG------TTGAA (1) (f) CAACTG---AAA--------TGAA (1) (g) CAAC-----CGAA--------TGAA (2) C rpsL LacZ-SB CCCTAGAATTCATAATA TATTATGAATTCTAGGG CCCTAGAATTCATAATACAG TATTATGAATTCTAGGG”
Retroviral integration into nucleosomes through DNA looping and sliding along the histone octamer
Wilson, M. D., Renault, L., Maskell, D. P., Ghoneim, M., Pye, V. E., Nans, A., Rueda, D. S., Cherepanov, P., & Costa, A. (2019) · Nature Communications · doi:10.1038/s41467-019-12007-w · Cited by 42
Self-citationRecent Advances in the Development of Integrase Inhibitors for HIV Treatment
Trivedi, J. S., Mahajan, D., Jaffe, R. J., Acharya, A., Mitra, D., & Byrareddy, S. N. (2020) · Current HIV/AIDS Reports · doi:10.1007/s11904-019-00480-3 · Cited by 60
Nucleoprotein Intermediates in HIV-1 DNA Integration Visualized by Atomic Force Microscopy
Kotova, S., Li, M., Dimitriadis, E. K., & Craigie, R. (2010) · Journal of Molecular Biology · doi:10.1016/j.jmb.2010.04.026 · Cited by 42
Engineered Hyperactive Integrase for Concerted HIV-1 DNA Integration
Li, M., Jurado, K. A., Lin, S., Engelman, A., & Craigie, R. (2014) · PLoS ONE · doi:10.1371/journal.pone.0105078 · Cited by 42
“The protein is soluble in solution and remains so when complexed viral DNA ends in the SSC [10,13].”
Self-citationRecent Advances in the Discovery of Small-Molecule Inhibitors of HIV-1 Integrase
Choi, E., Mallareddy, J. R., Lu, D., & Kolluru, S. (2018) · Future Science OA · doi:10.4155/fsoa-2018-0060 · Cited by 51
Augmenting Hit Identification by Virtual Screening Techniques in Small Molecule Drug Discovery
Yan, X. C., Sanders, J. M., Gao, Y.-D., Tudor, M., Haidle, A. M., Klein, D. J., Converso, A., Lesburg, C. A., Zang, Y., & Wood, H. B. (2020) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.0c00113 · Cited by 43
Multimodal mechanism of action of allosteric HIV-1 integrase inhibitors
Jurado, K. A., & Engelman, A. (2013) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2013.15 · Cited by 40
Self-citationDas, K., Balzarini, J. M., Miller, M. T., Maguire, A. R., DeStefano, J. J., & Arnold, E. (2016) · ACS Chemical Biology · doi:10.1021/acschembio.6b00187 · Cited by 44
“Active-site metal-chelating inhibitors, such as the HIV-1 in-tegrase-inhibiting drugs raltegravir, elvitegravir, and dolutegravir, chelate the catalytic metal ions of the intasome complex to block strand transfer 47,48 .”
Li, M., Oliveira Passos, D., Shan, Z., Smith, S. J., Sun, Q., Biswas, A., Choudhuri, I., Strutzenberg, T. S., Haldane, A., Deng, N., et al. (2023) · Science Advances · doi:10.1126/sciadv.adg5953 · Cited by 39
Peptides that inhibit HIV‐1 integrase by blocking its protein–protein interactions
Maes, M., Loyter, A., & Friedler, A. (2012) · FEBS Journal · doi:10.1111/j.1742-4658.2012.08680.x · Cited by 145
Molecular docking, QPLD, and ADME prediction studies on HIV-1 integrase leads
Tripathi, S. K., Selvaraj, C., Singh, S. K., & Reddy, K. K. (2012) · Medicinal Chemistry Research · doi:10.1007/s00044-011-9940-6 · Cited by 44
“Therefore, crystal structure of the Prototype Foamy Virus (PFV) in complex with Elvitegravir (GS9137) and Raltegravir (MK2048) has been used in current study as a reference (Hare et al., 2010a, b).”
BackgroundMethodInfluentialThe HIV-1 Integrase Monomer Induces a Specific Interaction with LTR DNA for Concerted Integration
Pandey, K. K., Bera, S., & Grandgenett, D. P. (2011) · Biochemistry · doi:10.1021/bi201247f · Cited by 39
“Both complexes possess a tetramer of IN (6, 8, 9) that produces their respective HIV 5 bp (11, 12) and PFV 4 bp (13) host site duplications.”
BackgroundMethodInfluentialHIV Drug Resistance and the Advent of Integrase Inhibitors
Quashie, P. K., Mésplède, T., & Wainberg, M. A. (2012) · Current Infectious Disease Reports · doi:10.1007/s11908-012-0305-1 · Cited by 46
“The recent elucidation of the full-length prototype foamy virus (PFV) structure [138], intasome [139], and strand transfer complexes (STCs) [140–142] with DNA ligands and, subsequently, with RAL, DTG, EVG, and MK-2048 [139, 140] has allowed for the generation of homology models of HIV-IN that can be used to “train” an…”
BackgroundSpeck‐Planche, A., Kleandrova, V. V., Luan, F., & Cordeiro, M. N. D. S. (2012) · Molecular BioSystems · doi:10.1039/c2mb25093d · Cited by 40
Targeting the Transposase Domain of the DNA Repair Component Metnase to Enhance Chemotherapy
Williamson, E. A., Damiani, L., Leitao, A., Hu, C., Hathaway, H., Oprea, T., Sklar, L., Shaheen, M., Bauman, J., Wang, W., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0313 · Cited by 39
“The chelation properties of raltegravir and elvitegravir were already described in X-ray structures of the integrase domain of prototype foamy virus (PFV) (22).”
BackgroundSlaughter, A., Jurado, K. A., Deng, N., Feng, L., Kessl, J. J., Shkriabai, N., Larue, R. C., Fadel, H. J., Patel, P. A., Jena, N., et al. (2014) · Retrovirology · doi:10.1186/s12977-014-0100-1 · Cited by 39
“through protein-protein and protein-DNA interactions [8-12].”
Self-citationMaehigashi, T., Ahn, S., Kim, U.-I., Lindenberger, J. J., Oo, A., Koneru, P. C., Mahboubi, B., Engelman, A., Kvaratskhelia, M., Kim, K., et al. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1009671 · Cited by 40
Self-citationCosnefroy, O., Tocco, A., Lesbats, P., Thierry, S., Calmels, C., Wiktorowicz, T., Reigadas, S., Kwon, Y., Cian, A. D., Desfarges, S., et al. (2011) · Journal of Virology · doi:10.1128/jvi.05425-11 · Cited by 47
“Additionally, since no interaction between the PFV integrase and hRAD51 was detected (data not shown), and in view of the high structural and functional similarities between PFV and HIV-1 proteins (15, 21, 28), our data suggest that the physical interaction between HIV-1 IN and hRAD51 is important for inhibition.”
BackgroundB′-protein phosphatase 2A is a functional binding partner of delta-retroviral integrase
Maertens, G. N. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkv1347 · Cited by 38
“Whilst the interaction between IN and viral LTR ends is DNA sequencespecific (5), the engagement of host DNA is much less so (6).”
Design, synthesis and antiviral activity of novel pyridazines
Wang, Z., Wang, M., Yao, X. X., Li, Y., Tan, J., Wang, L., Qiao, W., Geng, Y., Liu, Y., & Wang, Q. (2012) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2012.04.020 · Cited by 39
“Despite the lack of detailed structural information about HIV-1 IN/ DNA interactions, this speculative mechanism of action tends to be validated by the recent X-ray crystal structure of integrase from the prototype foamy virus (PFV-1 IN) in complex with its cognate viral DNA and strand transfer inhibitors [11,12].”
BackgroundHu, Z., & Kuritzkes, D. R. (2014) · Journal of Virology · doi:10.1128/jvi.00695-14 · Cited by 43
Mutations affecting interaction of integrase with TNPO3 do not prevent HIV-1 cDNA nuclear import
Cribier, A., Ségéral, E., Delelis, O., Parissi, V., Simon, A., Ruff, M., Bénarous, R., & Emiliani, S. (2011) · Retrovirology · doi:10.1186/1742-4690-8-104 · Cited by 50
“Recent retroviral intasome structures revealed a tetramer of IN formed by a dimer-of-dimers [28,67].”
Berta, D., Buigues, P. J., Badaoui, M., & Rosta, E. (2020) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2020.01.002 · Cited by 37
“Current inhibitors act on already different classes of targets, such as HIV integrase [90], RNase H [91], D-Ala-D-Ala Ligase [92], carbonic anhydrases [93], carboxypeptidase B [94] or adenosine deaminase [95] (Figure 3).”
BackgroundDifferential Sensitivities of Retroviruses to Integrase Strand Transfer Inhibitors
Koh, Y., Matreyek, K. A., & Engelman, A. (2011) · Journal of Virology · doi:10.1128/jvi.02541-10 · Cited by 37
“Recently determined X-ray crystal structures revealed that the drugs work by ejecting the 3 dA and its associated OH nucleophile from the IN active site (10, 11).”
BackgroundInfluentialSelf-citationBarski, M. S., Minnell, J. J., & Maertens, G. N. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.01877 · Cited by 37
Design of a series of bicyclic HIV-1 integrase inhibitors. Part 1: Selection of the scaffold
Jones, E. D., Vandegraaff, N., Le, G. T., Choi, N., Issa, W., Macfarlane, K., Thienthong, N., Winfield, L. J., Coates, J. A. V., Lü, L., et al. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.07.079 · Cited by 37
Metadata
- Authors
- Hare, S., Gupta, S. S., Valkov, E., Engelman, A., & Cherepanov, P.
- Affiliations
- Imperial College London (GB)
- The University of Queensland (AU)
- Dana-Farber Cancer Institute (US)
- Corresponding author
- Cherepanov, Peter
- Venue
- Nature
- Published
- 2010-01-31
- Volume
- 464
- Issue
- 7286
- Pages
- 232-236
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC2837123
- OpenAlex
- W2025344323
- Cited by
- 678
- References
- 50
- Citations by year
- 2026: 14 · 2025: 10 · 2024: 15 · 2023: 21 · 2022: 19 · 2021: 31 · 2020: 29 · 2019: 38 · 2018: 33 · 2017: 31 · 2016: 43 · 2015: 53 · 2014: 49 · 2013: 68 · 2012: 79
- FWCI
- 60.71
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Figshare (submittedVersion, cc-by)
- Spiral (Imperial College London) (submittedVersion)
- Funders
- Diamond Light Source
- Medical Research Council
- National Institute of Allergy and Infectious Diseases (R01AI070042, P30AI060354)
- Topics
- Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
- Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Keywords
- retroviral integrase, intasome, DNA strand transfer, HIV-1 integrase, integrase strand transfer inhibitors, raltegravir, elvitegravir, antiretroviral drug development, viral DNA integration, protein-DNA interactions
- MeSH terms
- DNA, Viral, Models, Molecular, Retroviridae, HIV-1, Protein Structure, Tertiary, Integrases, Catalytic Domain
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.